ELI LILLY & CO (LLY)
US5324571083 - Common Stock
The Best Biotech Stock to Invest $1,000 in Right Now
This stock may not be a slam dunk, but it's looking very promising.
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly's diabetes injection Mounjaro and obesity drug Zepbound.
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade.
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade.
Will Walmart Reach a Trillion-Dollar Market Cap by 2030?
This seemingly unlikely non-tech name quietly deserves to be on the list of contenders that could achieve the feat in the foreseeable future.
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
The company has too many weapons at its disposal.
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
The drugmaker continues to make headlines for all the right reasons.
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Want peace of mind about your investments? Consider these great stocks.
Exit Alert: 3 Stocks to Offload Before the Downturn
Discover why three top stocks to sell now are facing challenges in technology hardware, pharmaceuticals and automobile manufacturers.
Eli Lilly and Co.'s $2B Concord campus marks milestone for former Philip Morris site (PHOTOS)
Notable Friday Option Activity: BKNG, GS, LLY
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Food companies worried about weight loss drugs can just make healthier food, Eli Lilly CEO says
CEO David Ricks says he has received calls from Walmart and other companies seeking advice on how they should navigate the growing impact of weight loss drugs
Eli Lilly wants to replace Zepbound with an even stronger weight loss drug
Eli Lilly CEO David Ricks says the pharma giant has learned from its past mistakes and is already planning a Zepbound successor
Stock Market Hits Highs; Tame Inflation, Fed Meeting, Apple, Broadcom, Oracle, Tesla: Weekly Review
The Dow Jones fell amid weak-to-lackluster market breadth.
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
3 Stocks to Sell as Ozempic Surges in Popularity
GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity.
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Novo Nordisk's competition in the obesity drug market is heating up.
Employer coverage for weight-loss drugs rises sharply, survey finds
About one-third of U.S. employer health plans are offering coverage of GLP-1 drugs for both diabetes management and weight loss, up from last year, according to a survey of global employers released on Thursday by the International Foundation of Employee Benefit Plans. GLP-1 drugs for weight loss grew as a portion of employers' overall medical claims spending to 8.9% in 2024 from 6.9% in 2023, the trade group's survey found. GLP-1 drugs promote weight loss by reducing appetite and causing the stomach to empty more slowly.
Weight Loss Drugs: Are They Really Magic?
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs."
3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years
One of the best ways to spot winning stocks to buy is by spotting hot trends, such as artificial intelligence and obesity.
3 Stocks to Buy as Ozempic Surges in Popularity
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.
Want to Get Richer? 2 Top Stocks to Buy Now and Hold Forever.
These proven wealth builders have what it takes to deliver solid gains long-term.
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Wall Street analysts say this drug developer can more than double your money.
4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024
Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively.
Michigan’s Largest Insurer to Drop Weight-Loss Drug Coverage
Weight-loss drugs from Novo Nordisk A/S and Eli Lilly & Co. will lose coverage under many plans run by Michigan’s largest health insurer as companies grapple with whether the drugs are worth the cost.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
3 Stocks Quietly Preparing for a 10X Surge: June Edition
There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.